OOIR: Observatory of International Research

Papers

(The H4-Index of American Heart Journal is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design	161
Clinical applications of machine learning in the diagnosis, classification, and prediction of heart failure	97
Extracorporeal life support in patients with acute myocardial infarction complicated by cardiogenic shock - Design and rationale of the ECLS-SHOCK trial	89
Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance	89
Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO study	88
Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes—Systematic review and meta-analysis of randomized placebo-controlled trials	80
Shock in the cardiac intensive care unit: Changes in epidemiology and prognosis over time	78
Impact of the COVID-19 pandemic on patterns of outpatient cardiovascular care	73
Rationale and design of a large population study to validate software for the assessment of atrial fibrillation from data acquired by a consumer tracker or smartwatch: The Fitbit heart study	69
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficac	65
Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial	63
Rationale and design of the Women's Ischemia Trial to Reduce Events in Nonobstructive CAD (WARRIOR) trial	60
Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial	57
Randomized evaluation of beta blocker and ACE-inhibitor/angiotensin receptor blocker treatment in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA-BAT): Rationale and	56
Thrombosis in hospitalized patients with viral respiratory infections versus COVID-19	54
To Adjust or Not to Adjust: The Role of Different Covariates in Cardiovascular Observational Studies	50
Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE)	49
Trends of blood pressure control in the U.S. during the COVID-19 pandemic	49
Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: Rationale and design of the TRAVERSE study	46
Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial	45
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline chara	45
Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update	44
Plasma trimethylamine N-oxide (TMAO) levels predict future risk of coronary artery disease in apparently healthy individuals in the EPIC-Norfolk prospective population study	42
Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy	40
Diagnosis, prevention, and management of delirium in the intensive cardiac care unit	39

Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study	36
Financial burden, distress, and toxicity in cardiovascular disease	35
Reducing disparities in adverse pregnancy outcomes in the United States	35
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE	34
Improved outcomes in patients with severely depressed LVEF undergoing percutaneous coronary intervention with contemporary practices	34
Periodontal Disease, Atrial Fibrillation and Stroke	32
Association of gut-related metabolites with outcome in acute heart failure	31